Wegovy has gained attention as a powerful weight loss medication, especially for those struggling with obesity. However, if you're on Medicare or soon will be, you may be wonderi

US taxpayers spent an estimated $6 billion researching, developing, and implementing new blockbuster weight-loss drugs, according to new data shared with the Lever. Yet Americans are now paying pharmaceutical giants — including one in Denmark — up to eleven times more for these medicines than patients in other countries,

Health insurance companies are lobbying the Trump administration to reject Biden-era proposals that would expand Medicare and Medicaid prescription access to weight-loss medications such as Wegovy and Ozempic.

The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who can’t get the blockbuster drug through insurance.

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured and underinsured individuals to be able to pay cash for its weight

Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower doses in vials in August.

Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly five-fold to $35.8 billion between 2019 and 2023, a U.S. government watchdog's report showed this week.